VivoSeq
Gastroenterology

Alcoholic Fatty Liver Disease

71

Pipeline Programs↗

12

Active Trials↗

38

Companies Involved↗

Alcoholic Fatty Liver Disease is a moderately active landscape with 71 programs across 38 companies. The most active players are Bristol-Myers Squibb, Regeneron, Tasly Biopharmaceuticals Co., Ltd.. 15 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

78/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1T

Tasly Biopharmaceuticals Co., Ltd.

1 program

Phase 1EMD Serono logo

EMD Serono

2 programs

Phase 1Z

Zydus Therapeutics Inc.

1 program

Phase 2A

Akcea Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Canagliflozin

Wim Janssens

Fenofibrate

Jagotec

Dulaglutide

Eli Lilly

Niacin

AbbVie

Bempedoic Acid

Esperion Therapeutics, Inc.

Phase 17

Somatropin

EMD Serono

BMS-963272

Bristol-Myers Squibb

PF-06865571

Pfizer

Ginger

University of Rochester

ALN-PNP

Regeneron

Phase 234

Semaglutide

Novo Nordisk

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Dapagliflozin

AstraZeneca

Ezetimibe

Organon and Co

Aspirin

Bayer

Phase 37

Resmetirom

Madrigal Pharmaceuticals

Efruxifermin

Akero Therapeutics

Pioglitazone

Takeda

Combination Drug

Bayer

Trigonella Foenum-Graecum Seed Extract

Shiraz University of Medical Sciences

Approved15

Denosumab

Amgen

Alendronate Sodium

Mylan Pharmaceuticals Inc

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Telmisartan

Boehringer Ingelheim

Rosuvastatin

AstraZeneca

Analysis

Modality Breakdown

92%

Small molecule

71 of 77 classified programs — the dominant modality here.

8%ALL OTHERSPeptide34%Protein / enzyme23%Monoclonal antibody11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 100% of 78 pipeline programs.

Analysis

Trial Status

78

clinical trials

Completed43 · 55%
Unknown status11 · 14%
Terminated8 · 10%
Recruiting7 · 9%
Active, not recruiting4 · 5%
Withdrawn4 · 5%
Other1 · 1%

Clinical Trials

Trial Activity

78 trials

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
Recruiting·HHinova Pharmaceuticals Inc.·Phase 2·NCT07308548·80 enrolled
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Recruiting·TTanta University·Phase 2·NCT06863376·46 enrolled
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Recruiting·MMedanta, The Medicity, India·N/A·NCT06035874·100 enrolled
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
Recruiting·TTasly Biopharmaceuticals Co., Ltd.·Phase 1·NCT07128797·32 enrolled
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06368882·1,500 enrolled
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Recruiting·TTanta University·Phase 1/2·NCT07238985·50 enrolled
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
Recruiting·TTanta University·Phase 1/2·NCT07242222·50 enrolled
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Active, not recruiting·—·Phase 4·NCT05493761·72 enrolled
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Active, not recruiting·Akero Therapeutics logoAkero Therapeutics·Phase 3·NCT06161571·700 enrolled
Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease
Active, not recruiting·YYokohama City University·Phase 2·NCT06623539·360 enrolled
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Active, not recruiting·—·Phase 1/2·NCT07020377·60 enrolled
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
Enrolling by invitation·—·Phase 3·NCT06152991·196 enrolled
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
Completed·SShiraz University of Medical Sciences·Phase 2/3·NCT02303314·35 enrolled
Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
Completed·MMassachusetts General Hospital·Phase 1·NCT02726542·24 enrolled
Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease
Completed·—·Phase 2·NCT01147523·30 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)